PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Evaluated in control studies for the treatment of ocular allergy [PMID:14501441].
A commercial eye drop containing E. officinalis and M. chamomilla protected human corneal epithelial cells from UVB-induced cell death and oxidative stress [PMID:28704790].
Extracts demonstrated anti-neurotoxic properties by enhancing cell viability by 17.5 to 22.6% in human neuroblastoma cells exposed to amyloid-beta peptides [PMID:39684612].
Ethanol extract reduced UVB-induced apoptosis and ameliorated the increase of MMP-1 and MMP-3 in normal human dermal fibroblasts [PMID:30366440].
Optimized ethanol and acetone extracts exhibited strain-dependent antibacterial activity, with Gram-positive bacteria (S. aureus and Enterococcus sp.) being the most susceptible [PMID:40711608].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 39684612 (2024) — Chemical Characterization and Assessment of the Neuroprotective Potential of Euphrasia officinalis. · International journal of molecular sciences
- 2.PMID: 25207164 (2014) — Assessment of eyebright (euphrasia officinalis L.) extract activity in relation to human corneal cells using in vitro tests. · Balkan medical journal
- 3.PMID: 30366440 (2018) — Protective Effects of Euphrasia officinalis Extract against Ultraviolet B-Induced Photoaging in Normal Human Dermal Fibroblasts. · International journal of molecular sciences
- 4.PMID: 35948137 (2022) — Phenolic acids as chemotaxonomic markers able to differentiate the Euphrasia species. · Phytochemistry
- 5.PMID: 26000025 (2015)